All In Biotech

Drug Trial Radar · NCT02193867

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

Last checked: Nov 20, 2026Latest source record: Nov 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

10

Actual

Start

Jun 6, 2014

Primary completion

Oct 30, 2018

Study completion Oct 30, 2018

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 18, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 8 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an open-label, repeat-dose, study of sebelipase alfa in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D). Eligible participants received once-weekly infusions of sebelipase alfa for up to 3 years.

Conditions

  • Lysosomal Acid Lipase Deficiency

Interventions

  • Sebelipase AlfaDrug

    Sebelipase alfa is a recombinant human lysosomal acid lipase. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL-D. Dosing occurred once weekly for up to 3 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)Time frame: Screening through Month 37

Locations

5 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Kuopio, Finland

  • Site not named

    Naples, Italy

  • Site not named

    Birmingham, United Kingdom

  • Site not named

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.